Ghent, Belgium – 28 December 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...
in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology Ghent, Belgium – 7 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, ...
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis The Company will be hosting a further webcast with key opinion ...
alfapump was very effective in control of ascites, virtually eliminating the need for large volume paracentesis (LVP) long term Key POSEIDON investigators report alfapump is safe and effective tool ...
Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a significant risk of complications that are life threatening and require ...
Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...
Evidence-based recommendations on subcutaneous automated low-flow pump implantation for refractory ascites in adults. This involves inserting a pump under the skin to move excess fluid from the ...
in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology Recurrent or refractory ascites is a severe condition characterized by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results